<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02273726</url>
  </required_header>
  <id_info>
    <org_study_id>FGCL-4592-064</org_study_id>
    <nct_id>NCT02273726</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Participants With ESRD on Stable Dialysis</brief_title>
  <official_title>A Phase 3, Open-Label, Randomized, Active-Controlled Study of the Efficacy and Safety of Roxadustat (FG-4592) in the Maintenance Treatment of Anemia in Subjects With End Stage Renal Disease (ESRD) on Stable Dialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>FibroGen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Astellas Pharma Europe B.V.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>FibroGen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the efficacy and safety of roxadustat&#xD;
      compared with active control (epoetin alfa) for the maintenance treatment of anemia in&#xD;
      participants with ESRD on dialysis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will consist of three study periods as follows:&#xD;
&#xD;
        1. Screening Period of up to 6 weeks (8 weeks if on Mircera)&#xD;
&#xD;
        2. Treatment Period: a minimum of 52 weeks, a maximum of up to 3 years from the date last&#xD;
           participant is randomized. Minimum study duration for participants enrolled under&#xD;
           Protocol Amendment 1 or 2 may be less than 52 weeks&#xD;
&#xD;
        3. A Follow-up period of 4 weeks.&#xD;
&#xD;
      Participants will be randomized in a 1:1 ratio to receive either roxadustat or epoetin alfa&#xD;
      (active control) in an open-label manner.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 15, 2015</start_date>
  <completion_date type="Actual">September 19, 2018</completion_date>
  <primary_completion_date type="Actual">September 19, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>US (FDA) Submission: Mean Hb Change From Baseline to The Average Level During The Evaluation Period (Weeks 28 to 52), Regardless of Rescue Therapy</measure>
    <time_frame>Baseline (Day 1, Week 0), Weeks 28 to 52</time_frame>
    <description>Hb values under the influence of rescue therapy were not censored in the analysis. Rescue therapy for roxadustat treated participants was defined as recombinant erythropoietin or analogue (ESA) or red blood cell (RBC) transfusion, and rescue therapy for epoetin alfa treated participants was defined as RBC transfusion. Baseline Hb was defined the mean of up to 4 last central lab values prior to the first dose of study treatment. The intermittent missing Hb data was imputed for each treatment relying on non-missing data from all participants within each treatment group using the Monte Carlo Markov Chain (MCMC) imputation model, Monotone missing data were imputed by regression from its own treatment group.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ex-U.S. Submission: Mean Hb Change From Baseline to the Average Weeks 28 to 36, Without Having Received Rescue Therapy Within 6 Weeks Prior to and During This 8-Week Evaluation Period for Participants Enrolled Under the Original Protocol</measure>
    <time_frame>Baseline (Day 1, Week 0), Weeks 28 to 36</time_frame>
    <description>Hb values under the influence of rescue therapy were censored up to 6 weeks in the analysis. Rescue therapy for roxadustat treated participants was defined as recombinant erythropoietin or analogue (ESA) or RBC transfusion, and rescue therapy for epoetin alfa treated participants was defined as RBC transfusion. Baseline Hb was defined the mean of up to 4 last central lab values prior to the first dose of study treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>US (FDA Submission): Hb Responder Rate- Percentage of Participants With Mean Hb Level ≥10.0 g/dL Averaged Over Weeks 28 to 52, Regardless of Rescue Therapy</measure>
    <time_frame>Weeks 28 to 52</time_frame>
    <description>Hb values under the influence of rescue therapy were not censored in the analysis. Rescue therapy for roxadustat treated participants was defined as recombinant erythropoietin or analogue (ESA) or RBC transfusion, and rescue therapy for epoetin alfa treated participants was defined as RBC transfusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ex-U.S. Submission: Hb Responder Rate- Percentage of Participants With Mean Hb 10.0 to 12.0 g/dL Averaged Over Weeks 28 to 36, Censoring for Rescue Therapy</measure>
    <time_frame>Weeks 28 to 36</time_frame>
    <description>Hb values under the influence of a rescue therapy were censored up to 6 weeks in the analysis. Rescue therapy for roxadustat treated participants was defined as recombinant erythropoietin or analogue (ESA) or RBC transfusion, and rescue therapy for epoetin alfa treated participants was defined as RBC transfusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Low-Density Lipoprotein (LDL) Cholesterol Averaged Over Weeks 12 to 28</measure>
    <time_frame>Baseline (Day 1, Week 0), Weeks 12 to 28</time_frame>
    <description>Baseline LDL Cholesterol was defined as the last available value prior to the first dose of study treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Hb Levels Averaged Over Weeks 18 to 24 Regardless of Rescue Therapy in Participants Whose Baseline High Sensitivity C-Reactive Protein (Hs-CRP)&gt; Upper Limit of Normal (ULN)</measure>
    <time_frame>Baseline (Day 1, Week 0), Weeks 18 to 24</time_frame>
    <description>Hb values under the influence of rescue therapy were not censored in the analysis. Rescue therapy for roxadustat treated participants was defined as recombinant erythropoietin or analogue (ESA) or RBC transfusion, and rescue therapy for epoetin alfa treated participants was defined as RBC transfusion. Baseline Hb was defined the mean of up to 4 last central lab values prior to the first dose of study treatment. The intermittent missing Hb data was imputed for each treatment relying on non-missing data from all participants within each treatment group using the MCMC imputation model, Monotone missing data were imputed by regression from its own treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Monthly IV Iron Use Per Patient-Exposure-Month (PEM) During Weeks 28 to 52</measure>
    <time_frame>Weeks 28 to 52</time_frame>
    <description>Monthly iron use for each participant= Total IV iron in mg / [(last dose date - first dose date of study medication in the period)+1]/ 28.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First RBC Transfusion</measure>
    <time_frame>Baseline (Day 1, Week 0) up to last dose of study drug (maximum treatment duration was 183.7 weeks for roxadustat and 180.4 weeks for epoetin alfa)</time_frame>
    <description>Median time to event (weeks) was calculated using Kaplan Meier Survival Estimates.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Arterial Pressure (MAP) Averaged Over Weeks 20 to 28</measure>
    <time_frame>Baseline (Day 1, Week 0), Weeks 20 to 28</time_frame>
    <description>Baseline MAP was defined as the mean of values obtained within 6 weeks prior to the first dose of study treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Exacerbation of Hypertension During Weeks 28 to 52</measure>
    <time_frame>Weeks 28 to 52</time_frame>
    <description>An exacerbation of hypertension was defined as increase from baseline of ≥20 mmHg in systolic blood pressure (sBP) and sBP ≥170 mmHg or an increase from baseline of ≥15 mmHg in diastolic blood pressure (dBP) and dBP ≥100 mmHg. Median time to event (weeks) was calculated using Kaplan Meier Survival Estimates.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Short Form 36 (SF-36) Version 2 Physical Functioning Subscore and Vitality Subscore at Weeks 12 to 28</measure>
    <time_frame>Baseline (Day 1, Week 0), Weeks 12 to 28</time_frame>
    <description>The SF-36 V2 consists of 36 questions covering 8 health domains: physical functioning (10 items), bodily pain (2 items), role limitations due to physical problems (4 items), role limitations due to emotional problems (3 items), general health perceptions (5 items), mental health (5 items), social function (2 items), and vitality (4 items). The physical functioning subscore and vitality subscore are reported. Each scale was transformed into 0-100 score, with higher scores indicating better health status. Baseline score was defined as the last physical functioning value or vitality value, as applicable, prior to the first dose of study drug.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">741</enrollment>
  <condition>CKD Anemia in Stable Dialysis Patients</condition>
  <arm_group>
    <arm_group_label>Roxadustat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive roxadustat tablets, administered orally 3 times weekly (TIW). Initial roxadustat dose will be based on the participant's average prescribed erythropoietin stimulating agent (ESA) dose in the 4 weeks (if on epoetin or darbepoetin or 8 weeks (if on Mircera®) prior to randomization. Dose adjustments will be permitted to maintain a hemoglobin (Hb) level of approximately 11 grams (g)/deciliter (dL). The maximum roxadustat dose is 3.0 milligrams (mg)/kilogram (kg) per dose or 400 mg per administration (whichever is lower).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Epoetin Alfa</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants on hemodialysis (HD) will receive epoetin alfa, administered intravenously (IV) TIW and participants on home HD or peritoneal dialysis (PD) will receive epoetin alfa, administered subcutaneously (SC). Initial epoetin alfa dose will be based on the participant's average weekly prescribed ESA dose in 4 weeks prior to randomization if on epoetin or darbepoetin, and average monthly (4-week) prescribed ESA dose in 8 weeks prior to randomization if on Mircera®. In case of a change in route of administration from SC to IV (TIW), the initial dose of IV epoetin alfa will be determined by the investigator per local standard of care (SOC). Dose adjustments will follow the recommendations as per the approved country-specific product label (United States Package Insert [USPI] or Summary of Product Characteristics [SmPC]) or local SOC.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epoetin Alfa</intervention_name>
    <description>Epoetin alfa will be administered per dose and schedule specified in the arm.</description>
    <arm_group_label>Epoetin Alfa</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Roxadustat</intervention_name>
    <description>Roxadustat will be administered per dose and schedule specified in the arm.</description>
    <arm_group_label>Roxadustat</arm_group_label>
    <other_name>FG-4592</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Receiving dialysis for ESRD for ≥3 months. Incident dialysis participants (under&#xD;
             Amendment 1 and 2) receiving dialysis for ESRD for ≥ 2 weeks but ≤ 4 months at the&#xD;
             time of randomization&#xD;
&#xD;
          -  Participants must be on ESA for ≥ 8 weeks prior to screening; incident dialysis&#xD;
             participants must be on ESA for ≥ 4 weeks prior to screening.&#xD;
&#xD;
          -  Mean of the 3 most recent central lab Hb values during the Screening Period must be ≥&#xD;
             9.0 g/dL and ≤ 12.0 g/dL (for incident dialysis participants, mean of the 2 most&#xD;
             recent Hb values must be ≥ 8.5 g/dL and ≤ 12.0 g/dL); with an absolute difference of ≤&#xD;
             1.3 g/dL between the highest and the lowest value. Samples are obtained at least 4&#xD;
             days apart (2 days under Amendment 2) and the last Hb value must be within 10 days&#xD;
             prior to the randomization visit&#xD;
&#xD;
          -  Participants with ferritin level ≥ 100 nanograms (ng)/milliliter (mL) (&lt;100 ng/mL&#xD;
             under Amendment 2) or transferrin saturation (TSAT) ≥ 20% (&lt;20% under Amendment 2) at&#xD;
             screening may qualify upon receiving iron supplement (per local standard of care)&#xD;
&#xD;
          -  Participants with a serum folate and Vitamin B12 ≥ lower limit of normal (LLN) (&lt; LLN&#xD;
             under Amendment 2) at screening may qualify upon receiving supplement (per local&#xD;
             standard of care)&#xD;
&#xD;
          -  Participant's alanine aminotransferase (ALT) and aspartate aminotransferase (AST) are&#xD;
             ≤3x the upper limit of normal (ULN), and total bilirubin (TBL) is ≤1.5x ULN at&#xD;
             screening&#xD;
&#xD;
          -  Participant's body weight is 45 kilograms (kg) to 160 kg.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participant has received an red blood cell (RBC) transfusion within 8 weeks (4 weeks&#xD;
             under Amendment 2) prior to randomization&#xD;
&#xD;
          -  Participant has known history of myelodysplastic syndrome or multiple myeloma&#xD;
&#xD;
          -  Participant has known inherited disease such as thalassemia or sickle cell anemia or&#xD;
             other known causes for anemia other than chronic kidney disease.&#xD;
&#xD;
          -  Participant has known hemosiderosis, hemochromatosis, coagulation disorder,or&#xD;
             hypercoagulable condition&#xD;
&#xD;
          -  Participant has known chronic inflammatory disease that could cause anemia&#xD;
&#xD;
          -  Participant has anticipated surgery that is expected to cause blood loss&#xD;
&#xD;
          -  Participant has known gastrointestinal bleeding&#xD;
&#xD;
          -  Participant has history of chronic liver disease (for example, chronic infectious&#xD;
             hepatitis,chronic auto-immune liver disease,cirrhosis, or fibrosis of the liver)&#xD;
&#xD;
          -  Participant with New York Heart Association (NYHA) Class III or IV congestive heart&#xD;
             failure&#xD;
&#xD;
          -  Participant has had a heart attack, stroke, seizure, or a thrombotic/thromboembolic&#xD;
             event (for example, deep vein thrombosis or pulmonary embolism) within 12 weeks prior&#xD;
             to participating in the study&#xD;
&#xD;
          -  Participant has uncontrolled high blood pressure within 2 weeks prior to participating&#xD;
             in the study&#xD;
&#xD;
          -  Participant has a history of malignancy, except for the following: cancers determined&#xD;
             to be cured or in remission for ≥2 years, curatively resected basal cell or squamous&#xD;
             cell skin cancers, cervical cancer in situ, or resected colonic polyps.)&#xD;
&#xD;
          -  Participant is positive for human immunodeficiency virus (HIV), Hepatitis B surface&#xD;
             antigen, or anti-hepatitis C virus antibody&#xD;
&#xD;
          -  Participant with prior organ transplant who experience rejection within 6 months or on&#xD;
             high doses of immunosuppressive therapy&#xD;
&#xD;
          -  Participant has any of the following known untreated conditions; proliferative&#xD;
             diabetic retinopathy, diabetic macular edema, macular degeneration or retinal vein&#xD;
             occlusion.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Meraf Eyassu</last_name>
    <role>Study Director</role>
    <affiliation>FibroGen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Pine Bluff</city>
        <state>Arkansas</state>
        <zip>71603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91915</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <zip>91942</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90813</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Northridge</city>
        <state>California</state>
        <zip>91324</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Ontario</city>
        <state>California</state>
        <zip>91762</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Roseville</city>
        <state>California</state>
        <zip>95661</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>San Dimas</city>
        <state>California</state>
        <zip>91773</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>San Gabriel</city>
        <state>California</state>
        <zip>91776</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Whittier</city>
        <state>California</state>
        <zip>90603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Coral Springs</city>
        <state>Florida</state>
        <zip>33071</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Lauderdale Lakes</city>
        <state>Florida</state>
        <zip>33313</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33173</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33028</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Albany</city>
        <state>Georgia</state>
        <zip>31701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Meridian</city>
        <state>Idaho</state>
        <zip>83642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Pontiac</city>
        <state>Michigan</state>
        <zip>48341</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Brookhaven</city>
        <state>Mississippi</state>
        <zip>39601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Columbus</city>
        <state>Mississippi</state>
        <zip>39705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Gulfport</city>
        <state>Mississippi</state>
        <zip>39501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Tupelo</city>
        <state>Mississippi</state>
        <zip>38801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Creve Coeur</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Saint Ann</city>
        <state>Missouri</state>
        <zip>63074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Portsmouth</city>
        <state>New Hampshire</state>
        <zip>03885</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>North Brunswick</city>
        <state>New Jersey</state>
        <zip>08902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Gallup</city>
        <state>New Mexico</state>
        <zip>87301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>College Point</city>
        <state>New York</state>
        <zip>11356</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>11355</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>New Bern</city>
        <state>North Carolina</state>
        <zip>28562</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Rocky Mount</city>
        <state>North Carolina</state>
        <zip>27804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Aiken</city>
        <state>South Carolina</state>
        <zip>29803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Orangeburg</city>
        <state>South Carolina</state>
        <zip>29118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Sumter</city>
        <state>South Carolina</state>
        <zip>29150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37923</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37924</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76015-2368</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Edinburg</city>
        <state>Texas</state>
        <zip>78539</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76133</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76164</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Grand Prairie</city>
        <state>Texas</state>
        <zip>75050</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77099</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <zip>79430</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Mansfield</city>
        <state>Texas</state>
        <zip>76063</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Alexandria</city>
        <state>Virginia</state>
        <zip>20735</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Shorewood</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Caguas</city>
        <zip>00725</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>San Juan</city>
        <zip>00926</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 22, 2014</study_first_submitted>
  <study_first_submitted_qc>October 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2014</study_first_posted>
  <results_first_submitted>September 30, 2021</results_first_submitted>
  <results_first_submitted_qc>September 30, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">October 29, 2021</results_first_posted>
  <disposition_first_submitted>October 23, 2019</disposition_first_submitted>
  <disposition_first_submitted_qc>November 12, 2019</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">November 18, 2019</disposition_first_posted>
  <last_update_submitted>September 30, 2021</last_update_submitted>
  <last_update_submitted_qc>September 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anemia</keyword>
  <keyword>Chronic Kidney Disease</keyword>
  <keyword>Dialysis</keyword>
  <keyword>hemodialysis</keyword>
  <keyword>peritoneal dialysis</keyword>
  <keyword>hemoglobin</keyword>
  <keyword>End stage renal disease</keyword>
  <keyword>Stable Dialysis</keyword>
  <keyword>erythropoietins</keyword>
  <keyword>erythropoiesis stimulating agent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 18, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/26/NCT02273726/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 14, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/26/NCT02273726/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Participants were randomized in a 1:1 ratio to receive either roxadustat or epoetin alfa.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Roxadustat</title>
          <description>Participants received roxadustat tablets, administered orally 3 times weekly (TIW). Initial roxadustat dose was based on the participant's average prescribed erythropoietin stimulating agent (ESA) dose in the 4 weeks (if on epoetin or darbepoetin or 8 weeks (if on Mircera®) prior to randomization. Dose adjustments were permitted to maintain a hemoglobin (Hb) level of approximately 11 grams (g)/deciliter (dL). The maximum roxadustat dose was 3.0 milligrams (mg)/kilogram (kg) per dose or 400 mg per administration (whichever was lower). The maximum treatment duration was 183.7 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Epoetin Alfa</title>
          <description>Participants on hemodialysis (HD) received epoetin alfa, administered intravenously (IV) TIW and participants on home HD or peritoneal dialysis (PD) received epoetin alfa, administered subcutaneously (SC). Initial epoetin alfa dose was based on the participant's average weekly prescribed ESA dose in 4 weeks prior to randomization if on epoetin or darbepoetin, and average monthly (4-week) prescribed ESA dose in 8 weeks prior to randomization if on Mircera®. In case of a change in route of administration from SC to IV (TIW), the initial dose of IV epoetin alfa was determined by the investigator per local standard of care (SOC). Dose adjustments followed the recommendations as per the approved country-specific product label (United States Package Insert [USPI] or Summary of Product Characteristics [SmPC]) or local SOC. The maximum treatment duration was 180.4 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="370"/>
                <participants group_id="P2" count="371"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least 1 Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="370"/>
                <participants group_id="P2" count="370"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="127"/>
                <participants group_id="P2" count="183"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="243"/>
                <participants group_id="P2" count="188"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
                <participants group_id="P2" count="62"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Kidney transplant</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="39"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other than specified</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The intent to treat (ITT) population included all randomized participants.</population>
      <group_list>
        <group group_id="B1">
          <title>Roxadustat</title>
          <description>Participants received roxadustat tablets, administered orally TIW. Initial roxadustat dose was based on the participant's average prescribed ESA dose in the 4 weeks (if on epoetin or darbepoetin or 8 weeks (if on Mircera®) prior to randomization. Dose adjustments were permitted to maintain a Hb level of approximately 11 g/dL. The maximum roxadustat dose was 3.0 mg/kg per dose or 400 mg per administration (whichever was lower). The maximum treatment duration was 183.7 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Epoetin Alfa</title>
          <description>Participants on HD received epoetin alfa, administered IV TIW and participants on home HD or PD received epoetin alfa, administered SC. Initial epoetin alfa dose was based on the participant's average weekly prescribed ESA dose in 4 weeks prior to randomization if on epoetin or darbepoetin, and average monthly (4-week) prescribed ESA dose in 8 weeks prior to randomization if on Mircera®. In case of a change in route of administration from SC to IV (TIW), the initial dose of IV epoetin alfa was determined by the investigator per local SOC. Dose adjustments followed the recommendations as per the approved country-specific product label (USPI or SmPC) or local SOC. The maximum treatment duration was 180.4 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="370"/>
            <count group_id="B2" value="371"/>
            <count group_id="B3" value="741"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="253"/>
                    <measurement group_id="B2" value="246"/>
                    <measurement group_id="B3" value="499"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="117"/>
                    <measurement group_id="B2" value="125"/>
                    <measurement group_id="B3" value="242"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="183"/>
                    <measurement group_id="B2" value="156"/>
                    <measurement group_id="B3" value="339"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="187"/>
                    <measurement group_id="B2" value="215"/>
                    <measurement group_id="B3" value="402"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="137"/>
                    <measurement group_id="B2" value="129"/>
                    <measurement group_id="B3" value="266"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="233"/>
                    <measurement group_id="B2" value="242"/>
                    <measurement group_id="B3" value="475"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race</title>
              <category_list>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="165"/>
                    <measurement group_id="B2" value="184"/>
                    <measurement group_id="B3" value="349"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black/African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="158"/>
                    <measurement group_id="B2" value="156"/>
                    <measurement group_id="B3" value="314"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>American Indian/Alaskan Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>US (FDA) Submission: Mean Hb Change From Baseline to The Average Level During The Evaluation Period (Weeks 28 to 52), Regardless of Rescue Therapy</title>
        <description>Hb values under the influence of rescue therapy were not censored in the analysis. Rescue therapy for roxadustat treated participants was defined as recombinant erythropoietin or analogue (ESA) or red blood cell (RBC) transfusion, and rescue therapy for epoetin alfa treated participants was defined as RBC transfusion. Baseline Hb was defined the mean of up to 4 last central lab values prior to the first dose of study treatment. The intermittent missing Hb data was imputed for each treatment relying on non-missing data from all participants within each treatment group using the Monte Carlo Markov Chain (MCMC) imputation model, Monotone missing data were imputed by regression from its own treatment group.</description>
        <time_frame>Baseline (Day 1, Week 0), Weeks 28 to 52</time_frame>
        <population>ITT Population included all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Roxadustat</title>
            <description>Participants received roxadustat tablets, administered orally TIW. Initial roxadustat dose was based on the participant's average prescribed ESA dose in the 4 weeks (if on epoetin or darbepoetin or 8 weeks (if on Mircera®) prior to randomization. Dose adjustments were permitted to maintain a Hb level of approximately 11 g/dL. The maximum roxadustat dose was 3.0 mg/kg per dose or 400 mg per administration (whichever was lower). The maximum treatment duration was 183.7 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Epoetin Alfa</title>
            <description>Participants on HD received epoetin alfa, administered IV TIW and participants on home HD or PD received epoetin alfa, administered SC. Initial epoetin alfa dose was based on the participant's average weekly prescribed ESA dose in 4 weeks prior to randomization if on epoetin or darbepoetin, and average monthly (4-week) prescribed ESA dose in 8 weeks prior to randomization if on Mircera®. In case of a change in route of administration from SC to IV (TIW), the initial dose of IV epoetin alfa was determined by the investigator per local SOC. Dose adjustments followed the recommendations as per the approved country-specific product label (USPI or SmPC) or local SOC. The maximum treatment duration was 180.4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>US (FDA) Submission: Mean Hb Change From Baseline to The Average Level During The Evaluation Period (Weeks 28 to 52), Regardless of Rescue Therapy</title>
          <description>Hb values under the influence of rescue therapy were not censored in the analysis. Rescue therapy for roxadustat treated participants was defined as recombinant erythropoietin or analogue (ESA) or red blood cell (RBC) transfusion, and rescue therapy for epoetin alfa treated participants was defined as RBC transfusion. Baseline Hb was defined the mean of up to 4 last central lab values prior to the first dose of study treatment. The intermittent missing Hb data was imputed for each treatment relying on non-missing data from all participants within each treatment group using the Monte Carlo Markov Chain (MCMC) imputation model, Monotone missing data were imputed by regression from its own treatment group.</description>
          <population>ITT Population included all randomized participants.</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="370"/>
                <count group_id="O2" value="371"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.30" spread="0.661"/>
                    <measurement group_id="O2" value="10.31" spread="0.656"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Weeks 28 to 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.39" spread="0.934"/>
                    <measurement group_id="O2" value="-0.09" spread="0.838"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment comparison was made using the multiple imputation (MI) strategy by combining the results of analysis of covariance (ANCOVA) model with baseline Hb as a covariate, and treatment, ESA dependent incident dialysis within ≤4 months vs. &gt;4 months of starting dialysis when randomized, and other randomization stratification factors except mean qualifying screening hemoglobin (≤10.5 vs. &gt;10.5 g/dL) as fixed effects.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the 2-sided 95% confidence interval (CI) for the treatment difference in least square (LS) means from MI ANCOVA model between the 2 treatment groups lay entirely above -0.75 g/dL.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with MI</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.48</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.058</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.365</ci_lower_limit>
            <ci_upper_limit>0.591</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Ex-U.S. Submission: Mean Hb Change From Baseline to the Average Weeks 28 to 36, Without Having Received Rescue Therapy Within 6 Weeks Prior to and During This 8-Week Evaluation Period for Participants Enrolled Under the Original Protocol</title>
        <description>Hb values under the influence of rescue therapy were censored up to 6 weeks in the analysis. Rescue therapy for roxadustat treated participants was defined as recombinant erythropoietin or analogue (ESA) or RBC transfusion, and rescue therapy for epoetin alfa treated participants was defined as RBC transfusion. Baseline Hb was defined the mean of up to 4 last central lab values prior to the first dose of study treatment.</description>
        <time_frame>Baseline (Day 1, Week 0), Weeks 28 to 36</time_frame>
        <population>Per protocol set (PPS) population included all participants in full analysis set (FAS) population (all randomized participants who received at least 1 dose of study drug and had at least 1 postdose Hb assessment) who received at least 8 weeks of treatment and were without major protocol violations. 'Overall number of participants analyzed'=participants evaluable for this outcome measure. 'Number analyzed'=participants evaluable at specified timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Roxadustat</title>
            <description>Participants received roxadustat tablets, administered orally TIW. Initial roxadustat dose was based on the participant's average prescribed ESA dose in the 4 weeks (if on epoetin or darbepoetin or 8 weeks (if on Mircera®) prior to randomization. Dose adjustments were permitted to maintain a Hb level of approximately 11 g/dL. The maximum roxadustat dose was 3.0 mg/kg per dose or 400 mg per administration (whichever was lower). The maximum treatment duration was 183.7 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Epoetin Alfa</title>
            <description>Participants on HD received epoetin alfa, administered IV TIW and participants on home HD or PD received epoetin alfa, administered SC. Initial epoetin alfa dose was based on the participant's average weekly prescribed ESA dose in 4 weeks prior to randomization if on epoetin or darbepoetin, and average monthly (4-week) prescribed ESA dose in 8 weeks prior to randomization if on Mircera®. In case of a change in route of administration from SC to IV (TIW), the initial dose of IV epoetin alfa was determined by the investigator per local SOC. Dose adjustments followed the recommendations as per the approved country-specific product label (USPI or SmPC) or local SOC. The maximum treatment duration was 180.4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Ex-U.S. Submission: Mean Hb Change From Baseline to the Average Weeks 28 to 36, Without Having Received Rescue Therapy Within 6 Weeks Prior to and During This 8-Week Evaluation Period for Participants Enrolled Under the Original Protocol</title>
          <description>Hb values under the influence of rescue therapy were censored up to 6 weeks in the analysis. Rescue therapy for roxadustat treated participants was defined as recombinant erythropoietin or analogue (ESA) or RBC transfusion, and rescue therapy for epoetin alfa treated participants was defined as RBC transfusion. Baseline Hb was defined the mean of up to 4 last central lab values prior to the first dose of study treatment.</description>
          <population>Per protocol set (PPS) population included all participants in full analysis set (FAS) population (all randomized participants who received at least 1 dose of study drug and had at least 1 postdose Hb assessment) who received at least 8 weeks of treatment and were without major protocol violations. 'Overall number of participants analyzed'=participants evaluable for this outcome measure. 'Number analyzed'=participants evaluable at specified timepoint.</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="303"/>
                <count group_id="O2" value="324"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="303"/>
                    <count group_id="O2" value="324"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.33" spread="0.639"/>
                    <measurement group_id="O2" value="10.35" spread="0.614"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Weeks 28 to 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="263"/>
                    <count group_id="O2" value="293"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.54" spread="1.022"/>
                    <measurement group_id="O2" value="-0.03" spread="0.897"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment comparison was made using a mixed model of repeated measures (MMRM) with baseline Hb as a covariate, and treatment, visit, visit-by-treatment interaction, ESA dependent incident dialysis within ≤4 months vs. &gt;4 months of starting dialysis when randomized, and randomization stratification factors except mean qualifying screening Hb (≤10.5 vs. &gt;10.5 g/dL) as fixed effects.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority was established when the 2-sided 95% CI for the difference of LS means between the 2 treatment groups using the MMRM model lay entirely above -0.75 g/dL.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.55</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.072</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.404</ci_lower_limit>
            <ci_upper_limit>0.687</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>US (FDA Submission): Hb Responder Rate- Percentage of Participants With Mean Hb Level ≥10.0 g/dL Averaged Over Weeks 28 to 52, Regardless of Rescue Therapy</title>
        <description>Hb values under the influence of rescue therapy were not censored in the analysis. Rescue therapy for roxadustat treated participants was defined as recombinant erythropoietin or analogue (ESA) or RBC transfusion, and rescue therapy for epoetin alfa treated participants was defined as RBC transfusion.</description>
        <time_frame>Weeks 28 to 52</time_frame>
        <population>FAS population included all randomized participants who received at least 1 dose of study drug and had at least 1 postdose Hb assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Roxadustat</title>
            <description>Participants received roxadustat tablets, administered orally TIW. Initial roxadustat dose was based on the participant's average prescribed ESA dose in the 4 weeks (if on epoetin or darbepoetin or 8 weeks (if on Mircera®) prior to randomization. Dose adjustments were permitted to maintain a Hb level of approximately 11 g/dL. The maximum roxadustat dose was 3.0 mg/kg per dose or 400 mg per administration (whichever was lower). The maximum treatment duration was 183.7 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Epoetin Alfa</title>
            <description>Participants on HD received epoetin alfa, administered IV TIW and participants on home HD or PD received epoetin alfa, administered SC. Initial epoetin alfa dose was based on the participant's average weekly prescribed ESA dose in 4 weeks prior to randomization if on epoetin or darbepoetin, and average monthly (4-week) prescribed ESA dose in 8 weeks prior to randomization if on Mircera®. In case of a change in route of administration from SC to IV (TIW), the initial dose of IV epoetin alfa was determined by the investigator per local SOC. Dose adjustments followed the recommendations as per the approved country-specific product label (USPI or SmPC) or local SOC. The maximum treatment duration was 180.4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>US (FDA Submission): Hb Responder Rate- Percentage of Participants With Mean Hb Level ≥10.0 g/dL Averaged Over Weeks 28 to 52, Regardless of Rescue Therapy</title>
          <description>Hb values under the influence of rescue therapy were not censored in the analysis. Rescue therapy for roxadustat treated participants was defined as recombinant erythropoietin or analogue (ESA) or RBC transfusion, and rescue therapy for epoetin alfa treated participants was defined as RBC transfusion.</description>
          <population>FAS population included all randomized participants who received at least 1 dose of study drug and had at least 1 postdose Hb assessment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="369"/>
                <count group_id="O2" value="370"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.1"/>
                    <measurement group_id="O2" value="58.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For the difference of responder rates between 2 treatment groups, the CI analyzed was from the Miettinen &amp; Nurminen approach adjusting for randomization stratification factors.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of the 2-sided 95% CI for the treatment difference for the responder rates (roxadustat minus epoetin alfa) calculated based on the Miettinen &amp; Nurminen approach, adjusting for stratification factors, was greater than -15%.</non_inferiority_desc>
            <param_type>Responder Rate Difference</param_type>
            <param_value>7.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9</ci_lower_limit>
            <ci_upper_limit>14.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ex-U.S. Submission: Hb Responder Rate- Percentage of Participants With Mean Hb 10.0 to 12.0 g/dL Averaged Over Weeks 28 to 36, Censoring for Rescue Therapy</title>
        <description>Hb values under the influence of a rescue therapy were censored up to 6 weeks in the analysis. Rescue therapy for roxadustat treated participants was defined as recombinant erythropoietin or analogue (ESA) or RBC transfusion, and rescue therapy for epoetin alfa treated participants was defined as RBC transfusion.</description>
        <time_frame>Weeks 28 to 36</time_frame>
        <population>The PPS population included all participants in the FAS population (all randomized participants who received at least 1 dose of study drug and had at least 1 postdose Hb assessment) who received at least 8 weeks of treatment, had at least 1 valid postdose Hb assessment and were without major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>Roxadustat</title>
            <description>Participants received roxadustat tablets, administered orally TIW. Initial roxadustat dose was based on the participant's average prescribed ESA dose in the 4 weeks (if on epoetin or darbepoetin or 8 weeks (if on Mircera®) prior to randomization. Dose adjustments were permitted to maintain a Hb level of approximately 11 g/dL. The maximum roxadustat dose was 3.0 mg/kg per dose or 400 mg per administration (whichever was lower). The maximum treatment duration was 183.7 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Epoetin Alfa</title>
            <description>Participants on HD received epoetin alfa, administered IV TIW and participants on home HD or PD received epoetin alfa, administered SC. Initial epoetin alfa dose was based on the participant's average weekly prescribed ESA dose in 4 weeks prior to randomization if on epoetin or darbepoetin, and average monthly (4-week) prescribed ESA dose in 8 weeks prior to randomization if on Mircera®. In case of a change in route of administration from SC to IV (TIW), the initial dose of IV epoetin alfa was determined by the investigator per local SOC. Dose adjustments followed the recommendations as per the approved country-specific product label (USPI or SmPC) or local SOC. The maximum treatment duration was 180.4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Ex-U.S. Submission: Hb Responder Rate- Percentage of Participants With Mean Hb 10.0 to 12.0 g/dL Averaged Over Weeks 28 to 36, Censoring for Rescue Therapy</title>
          <description>Hb values under the influence of a rescue therapy were censored up to 6 weeks in the analysis. Rescue therapy for roxadustat treated participants was defined as recombinant erythropoietin or analogue (ESA) or RBC transfusion, and rescue therapy for epoetin alfa treated participants was defined as RBC transfusion.</description>
          <population>The PPS population included all participants in the FAS population (all randomized participants who received at least 1 dose of study drug and had at least 1 postdose Hb assessment) who received at least 8 weeks of treatment, had at least 1 valid postdose Hb assessment and were without major protocol violations.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="334"/>
                <count group_id="O2" value="352"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.1"/>
                    <measurement group_id="O2" value="60.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For the difference of responder rates between 2 treatment groups, the CI analyzed was from the Miettinen &amp; Nurminen approach adjusting for randomization stratification factors.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of the 2-sided 95% CI for the treatment difference for the responder rates (roxadustat minus epoetin alfa) calculated based on the Miettinen &amp; Nurminen approach, adjusting for stratification factors, was greater than -15%.</non_inferiority_desc>
            <param_type>Responder Rate Difference</param_type>
            <param_value>2.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.3</ci_lower_limit>
            <ci_upper_limit>9.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Low-Density Lipoprotein (LDL) Cholesterol Averaged Over Weeks 12 to 28</title>
        <description>Baseline LDL Cholesterol was defined as the last available value prior to the first dose of study treatment.</description>
        <time_frame>Baseline (Day 1, Week 0), Weeks 12 to 28</time_frame>
        <population>FAS population included all randomized participants who received at least 1 dose of study drug and had at least 1 postdose Hb assessment. Here, 'Number analyzed' signifies participants evaluable for this outcome measure at specified timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Roxadustat</title>
            <description>Participants received roxadustat tablets, administered orally TIW. Initial roxadustat dose was based on the participant's average prescribed ESA dose in the 4 weeks (if on epoetin or darbepoetin or 8 weeks (if on Mircera®) prior to randomization. Dose adjustments were permitted to maintain a Hb level of approximately 11 g/dL. The maximum roxadustat dose was 3.0 mg/kg per dose or 400 mg per administration (whichever was lower). The maximum treatment duration was 183.7 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Epoetin Alfa</title>
            <description>Participants on HD received epoetin alfa, administered IV TIW and participants on home HD or PD received epoetin alfa, administered SC. Initial epoetin alfa dose was based on the participant's average weekly prescribed ESA dose in 4 weeks prior to randomization if on epoetin or darbepoetin, and average monthly (4-week) prescribed ESA dose in 8 weeks prior to randomization if on Mircera®. In case of a change in route of administration from SC to IV (TIW), the initial dose of IV epoetin alfa was determined by the investigator per local SOC. Dose adjustments followed the recommendations as per the approved country-specific product label (USPI or SmPC) or local SOC. The maximum treatment duration was 180.4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Low-Density Lipoprotein (LDL) Cholesterol Averaged Over Weeks 12 to 28</title>
          <description>Baseline LDL Cholesterol was defined as the last available value prior to the first dose of study treatment.</description>
          <population>FAS population included all randomized participants who received at least 1 dose of study drug and had at least 1 postdose Hb assessment. Here, 'Number analyzed' signifies participants evaluable for this outcome measure at specified timepoint.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="369"/>
                <count group_id="O2" value="370"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="369"/>
                    <count group_id="O2" value="370"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.53" spread="34.009"/>
                    <measurement group_id="O2" value="84.45" spread="34.124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Weeks 12 to 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="327"/>
                    <count group_id="O2" value="354"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.70" spread="23.068"/>
                    <measurement group_id="O2" value="1.23" spread="22.389"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment comparison was made using a MMRM with baseline as a covariate, and treatment, visit, visit-by-treatment interaction, ESA dependent incident dialysis within ≤4 months vs. &gt;4 months of starting dialysis when randomized, and randomization stratification factors as fixed effects.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Superiority was declared if the upper bound of the 2-sided 95% CI of the difference between roxadustat and epoetin alfa (roxadustat - epoetin alpha) was less than 0.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>-14.67</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.514</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-17.640</ci_lower_limit>
            <ci_upper_limit>-11.695</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Hb Levels Averaged Over Weeks 18 to 24 Regardless of Rescue Therapy in Participants Whose Baseline High Sensitivity C-Reactive Protein (Hs-CRP)&gt; Upper Limit of Normal (ULN)</title>
        <description>Hb values under the influence of rescue therapy were not censored in the analysis. Rescue therapy for roxadustat treated participants was defined as recombinant erythropoietin or analogue (ESA) or RBC transfusion, and rescue therapy for epoetin alfa treated participants was defined as RBC transfusion. Baseline Hb was defined the mean of up to 4 last central lab values prior to the first dose of study treatment. The intermittent missing Hb data was imputed for each treatment relying on non-missing data from all participants within each treatment group using the MCMC imputation model, Monotone missing data were imputed by regression from its own treatment group.</description>
        <time_frame>Baseline (Day 1, Week 0), Weeks 18 to 24</time_frame>
        <population>FAS population included all randomized participants who received at least 1 dose of study drug and had at least 1 postdose Hb assessment. Here, 'Overall number of participants analyzed' signifies participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Roxadustat</title>
            <description>Participants received roxadustat tablets, administered orally TIW. Initial roxadustat dose was based on the participant's average prescribed ESA dose in the 4 weeks (if on epoetin or darbepoetin or 8 weeks (if on Mircera®) prior to randomization. Dose adjustments were permitted to maintain a Hb level of approximately 11 g/dL. The maximum roxadustat dose was 3.0 mg/kg per dose or 400 mg per administration (whichever was lower). The maximum treatment duration was 183.7 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Epoetin Alfa</title>
            <description>Participants on HD received epoetin alfa, administered IV TIW and participants on home HD or PD received epoetin alfa, administered SC. Initial epoetin alfa dose was based on the participant's average weekly prescribed ESA dose in 4 weeks prior to randomization if on epoetin or darbepoetin, and average monthly (4-week) prescribed ESA dose in 8 weeks prior to randomization if on Mircera®. In case of a change in route of administration from SC to IV (TIW), the initial dose of IV epoetin alfa was determined by the investigator per local SOC. Dose adjustments followed the recommendations as per the approved country-specific product label (USPI or SmPC) or local SOC. The maximum treatment duration was 180.4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hb Levels Averaged Over Weeks 18 to 24 Regardless of Rescue Therapy in Participants Whose Baseline High Sensitivity C-Reactive Protein (Hs-CRP)&gt; Upper Limit of Normal (ULN)</title>
          <description>Hb values under the influence of rescue therapy were not censored in the analysis. Rescue therapy for roxadustat treated participants was defined as recombinant erythropoietin or analogue (ESA) or RBC transfusion, and rescue therapy for epoetin alfa treated participants was defined as RBC transfusion. Baseline Hb was defined the mean of up to 4 last central lab values prior to the first dose of study treatment. The intermittent missing Hb data was imputed for each treatment relying on non-missing data from all participants within each treatment group using the MCMC imputation model, Monotone missing data were imputed by regression from its own treatment group.</description>
          <population>FAS population included all randomized participants who received at least 1 dose of study drug and had at least 1 postdose Hb assessment. Here, 'Overall number of participants analyzed' signifies participants evaluable for this outcome measure.</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="189"/>
                <count group_id="O2" value="176"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.30" spread="0.616"/>
                    <measurement group_id="O2" value="10.24" spread="0.630"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Weeks 18-24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.61" spread="1.020"/>
                    <measurement group_id="O2" value="-0.03" spread="0.940"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment comparison was made using the MI strategy by combining the results of ANCOVA model with baseline Hb as a covariate, and treatment, ESA dependent incident dialysis within ≤4 months vs. &gt;4 months of starting dialysis when randomized, and other randomization stratification factors except mean qualifying screening Hb (≤10.5 vs. &gt;10.5 g/dL) as fixed effects.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority margin was fixed as a difference of -0.75.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with MI</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.69</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.093</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.503</ci_lower_limit>
            <ci_upper_limit>0.869</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Monthly IV Iron Use Per Patient-Exposure-Month (PEM) During Weeks 28 to 52</title>
        <description>Monthly iron use for each participant= Total IV iron in mg / [(last dose date - first dose date of study medication in the period)+1]/ 28.</description>
        <time_frame>Weeks 28 to 52</time_frame>
        <population>FAS population included all randomized participants who received at least 1 dose of study drug and had at least 1 postdose Hb assessment. Here, 'Overall number of participants analyzed' signifies participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Roxadustat</title>
            <description>Participants received roxadustat tablets, administered orally TIW. Initial roxadustat dose was based on the participant's average prescribed ESA dose in the 4 weeks (if on epoetin or darbepoetin or 8 weeks (if on Mircera®) prior to randomization. Dose adjustments were permitted to maintain a Hb level of approximately 11 g/dL. The maximum roxadustat dose was 3.0 mg/kg per dose or 400 mg per administration (whichever was lower). The maximum treatment duration was 183.7 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Epoetin Alfa</title>
            <description>Participants on HD received epoetin alfa, administered IV TIW and participants on home HD or PD received epoetin alfa, administered SC. Initial epoetin alfa dose was based on the participant's average weekly prescribed ESA dose in 4 weeks prior to randomization if on epoetin or darbepoetin, and average monthly (4-week) prescribed ESA dose in 8 weeks prior to randomization if on Mircera®. In case of a change in route of administration from SC to IV (TIW), the initial dose of IV epoetin alfa was determined by the investigator per local SOC. Dose adjustments followed the recommendations as per the approved country-specific product label (USPI or SmPC) or local SOC. The maximum treatment duration was 180.4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Average Monthly IV Iron Use Per Patient-Exposure-Month (PEM) During Weeks 28 to 52</title>
          <description>Monthly iron use for each participant= Total IV iron in mg / [(last dose date - first dose date of study medication in the period)+1]/ 28.</description>
          <population>FAS population included all randomized participants who received at least 1 dose of study drug and had at least 1 postdose Hb assessment. Here, 'Overall number of participants analyzed' signifies participants evaluable for this outcome measure.</population>
          <units>mg/PEM</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="286"/>
                <count group_id="O2" value="319"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.07" spread="53.375"/>
                    <measurement group_id="O2" value="37.02" spread="106.778"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment comparison was made using an ANCOVA model with baseline iron repletion status, treatment, ESA dependent incident dialysis within ≤4 months vs. &gt;4 months of starting dialysis when randomized, and randomization stratification factors as fixed effects.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.00091</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>Rank ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-20.14</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.975</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-33.842</ci_lower_limit>
            <ci_upper_limit>-6.445</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First RBC Transfusion</title>
        <description>Median time to event (weeks) was calculated using Kaplan Meier Survival Estimates.</description>
        <time_frame>Baseline (Day 1, Week 0) up to last dose of study drug (maximum treatment duration was 183.7 weeks for roxadustat and 180.4 weeks for epoetin alfa)</time_frame>
        <population>FAS population included all randomized participants who received at least 1 dose of study drug and had at least 1 postdose Hb assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Roxadustat</title>
            <description>Participants received roxadustat tablets, administered orally TIW. Initial roxadustat dose was based on the participant's average prescribed ESA dose in the 4 weeks (if on epoetin or darbepoetin or 8 weeks (if on Mircera®) prior to randomization. Dose adjustments were permitted to maintain a Hb level of approximately 11 g/dL. The maximum roxadustat dose was 3.0 mg/kg per dose or 400 mg per administration (whichever was lower). The maximum treatment duration was 183.7 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Epoetin Alfa</title>
            <description>Participants on HD received epoetin alfa, administered IV TIW and participants on home HD or PD received epoetin alfa, administered SC. Initial epoetin alfa dose was based on the participant's average weekly prescribed ESA dose in 4 weeks prior to randomization if on epoetin or darbepoetin, and average monthly (4-week) prescribed ESA dose in 8 weeks prior to randomization if on Mircera®. In case of a change in route of administration from SC to IV (TIW), the initial dose of IV epoetin alfa was determined by the investigator per local SOC. Dose adjustments followed the recommendations as per the approved country-specific product label (USPI or SmPC) or local SOC. The maximum treatment duration was 180.4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First RBC Transfusion</title>
          <description>Median time to event (weeks) was calculated using Kaplan Meier Survival Estimates.</description>
          <population>FAS population included all randomized participants who received at least 1 dose of study drug and had at least 1 postdose Hb assessment.</population>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="369"/>
                <count group_id="O2" value="370"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Due to smaller number of participants with an event (any use of RBC transfusion), median and 95% CI could not be calculated.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Due to smaller number of participants with an event (any use of RBC transfusion), median and 95% CI could not be calculated.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis was done using a Cox Proportional Hazards model adjusting for baseline Hb and other stratification factors except mean qualifying screening Hb (≤10.5 vs. &gt;10.5 g/dL) as fixed effects.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority margin for the difference between groups was 1.8.</non_inferiority_desc>
            <p_value>0.0337</p_value>
            <method>Cox Proportional Hazards model</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.466</ci_lower_limit>
            <ci_upper_limit>0.970</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Arterial Pressure (MAP) Averaged Over Weeks 20 to 28</title>
        <description>Baseline MAP was defined as the mean of values obtained within 6 weeks prior to the first dose of study treatment.</description>
        <time_frame>Baseline (Day 1, Week 0), Weeks 20 to 28</time_frame>
        <population>FAS population included all randomized participants who received at least 1 dose of study drug and had at least 1 postdose Hb assessment. Here, 'Number analyzed' signifies participants evaluable for this outcome measure at specified timepoints.</population>
        <group_list>
          <group group_id="O1">
            <title>Roxadustat</title>
            <description>Participants received roxadustat tablets, administered orally TIW. Initial roxadustat dose was based on the participant's average prescribed ESA dose in the 4 weeks (if on epoetin or darbepoetin or 8 weeks (if on Mircera®) prior to randomization. Dose adjustments were permitted to maintain a Hb level of approximately 11 g/dL. The maximum roxadustat dose was 3.0 mg/kg per dose or 400 mg per administration (whichever was lower). The maximum treatment duration was 183.7 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Epoetin Alfa</title>
            <description>Participants on HD received epoetin alfa, administered IV TIW and participants on home HD or PD received epoetin alfa, administered SC. Initial epoetin alfa dose was based on the participant's average weekly prescribed ESA dose in 4 weeks prior to randomization if on epoetin or darbepoetin, and average monthly (4-week) prescribed ESA dose in 8 weeks prior to randomization if on Mircera®. In case of a change in route of administration from SC to IV (TIW), the initial dose of IV epoetin alfa was determined by the investigator per local SOC. Dose adjustments followed the recommendations as per the approved country-specific product label (USPI or SmPC) or local SOC. The maximum treatment duration was 180.4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Arterial Pressure (MAP) Averaged Over Weeks 20 to 28</title>
          <description>Baseline MAP was defined as the mean of values obtained within 6 weeks prior to the first dose of study treatment.</description>
          <population>FAS population included all randomized participants who received at least 1 dose of study drug and had at least 1 postdose Hb assessment. Here, 'Number analyzed' signifies participants evaluable for this outcome measure at specified timepoints.</population>
          <units>millimeters of mercury (mmHg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="369"/>
                <count group_id="O2" value="370"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="369"/>
                    <count group_id="O2" value="370"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101.41" spread="12.591"/>
                    <measurement group_id="O2" value="100.34" spread="12.350"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Weeks 20 to 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="304"/>
                    <count group_id="O2" value="338"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.46" spread="10.933"/>
                    <measurement group_id="O2" value="0.04" spread="10.489"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment comparison was made using MMRM with baseline as a covariate, and treatment, visit, visit-by-treatment interaction, ESA dependent incident dialysis within ≤4 months vs. &gt;4 months of starting dialysis when randomized, and randomization stratification factors as fixed effects.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Superiority was declared if the upper bound of the 2-sided 95% CI of the difference between roxadustat and epoetin alfa (roxadustat - epoetin alpha) was less than 0.</non_inferiority_desc>
            <p_value>0.3500</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.69</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.739</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.760</ci_lower_limit>
            <ci_upper_limit>2.142</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Exacerbation of Hypertension During Weeks 28 to 52</title>
        <description>An exacerbation of hypertension was defined as increase from baseline of ≥20 mmHg in systolic blood pressure (sBP) and sBP ≥170 mmHg or an increase from baseline of ≥15 mmHg in diastolic blood pressure (dBP) and dBP ≥100 mmHg. Median time to event (weeks) was calculated using Kaplan Meier Survival Estimates.</description>
        <time_frame>Weeks 28 to 52</time_frame>
        <population>FAS population included all randomized participants who received at least 1 dose of study drug and had at least 1 postdose Hb assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Roxadustat</title>
            <description>Participants received roxadustat tablets, administered orally TIW. Initial roxadustat dose was based on the participant's average prescribed ESA dose in the 4 weeks (if on epoetin or darbepoetin or 8 weeks (if on Mircera®) prior to randomization. Dose adjustments were permitted to maintain a Hb level of approximately 11 g/dL. The maximum roxadustat dose was 3.0 mg/kg per dose or 400 mg per administration (whichever was lower). The maximum treatment duration was 183.7 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Epoetin Alfa</title>
            <description>Participants on HD received epoetin alfa, administered IV TIW and participants on home HD or PD received epoetin alfa, administered SC. Initial epoetin alfa dose was based on the participant's average weekly prescribed ESA dose in 4 weeks prior to randomization if on epoetin or darbepoetin, and average monthly (4-week) prescribed ESA dose in 8 weeks prior to randomization if on Mircera®. In case of a change in route of administration from SC to IV (TIW), the initial dose of IV epoetin alfa was determined by the investigator per local SOC. Dose adjustments followed the recommendations as per the approved country-specific product label (USPI or SmPC) or local SOC. The maximum treatment duration was 180.4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Exacerbation of Hypertension During Weeks 28 to 52</title>
          <description>An exacerbation of hypertension was defined as increase from baseline of ≥20 mmHg in systolic blood pressure (sBP) and sBP ≥170 mmHg or an increase from baseline of ≥15 mmHg in diastolic blood pressure (dBP) and dBP ≥100 mmHg. Median time to event (weeks) was calculated using Kaplan Meier Survival Estimates.</description>
          <population>FAS population included all randomized participants who received at least 1 dose of study drug and had at least 1 postdose Hb assessment.</population>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="369"/>
                <count group_id="O2" value="370"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Due to smaller number of participants with an event (exacerbation hypertension), median and 95% CI could not be calculated.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Due to smaller number of participants with an event (exacerbation hypertension), median and 95% CI could not be calculated.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Short Form 36 (SF-36) Version 2 Physical Functioning Subscore and Vitality Subscore at Weeks 12 to 28</title>
        <description>The SF-36 V2 consists of 36 questions covering 8 health domains: physical functioning (10 items), bodily pain (2 items), role limitations due to physical problems (4 items), role limitations due to emotional problems (3 items), general health perceptions (5 items), mental health (5 items), social function (2 items), and vitality (4 items). The physical functioning subscore and vitality subscore are reported. Each scale was transformed into 0-100 score, with higher scores indicating better health status. Baseline score was defined as the last physical functioning value or vitality value, as applicable, prior to the first dose of study drug.</description>
        <time_frame>Baseline (Day 1, Week 0), Weeks 12 to 28</time_frame>
        <population>FAS Population included all randomized/enrolled participants who received at least 1 dose of study drug and had baseline and at least 1 postdose Hb assessment. Here, 'Overall number of participants analyzed' signifies participants evaluable for this outcome measure and 'Number Analyzed' signifies participants evaluable for this outcome measure at specified timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Roxadustat</title>
            <description>Participants received roxadustat tablets, administered orally TIW. Initial roxadustat dose was based on the participant's average prescribed ESA dose in the 4 weeks (if on epoetin or darbepoetin or 8 weeks (if on Mircera®) prior to randomization. Dose adjustments were permitted to maintain a Hb level of approximately 11 g/dL. The maximum roxadustat dose was 3.0 mg/kg per dose or 400 mg per administration (whichever was lower). The maximum treatment duration was 183.7 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Epoetin Alfa</title>
            <description>Participants on HD received epoetin alfa, administered IV TIW and participants on home HD or PD received epoetin alfa, administered SC. Initial epoetin alfa dose was based on the participant's average weekly prescribed ESA dose in 4 weeks prior to randomization if on epoetin or darbepoetin, and average monthly (4-week) prescribed ESA dose in 8 weeks prior to randomization if on Mircera®. In case of a change in route of administration from SC to IV (TIW), the initial dose of IV epoetin alfa was determined by the investigator per local SOC. Dose adjustments followed the recommendations as per the approved country-specific product label (USPI or SmPC) or local SOC. The maximum treatment duration was 180.4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Short Form 36 (SF-36) Version 2 Physical Functioning Subscore and Vitality Subscore at Weeks 12 to 28</title>
          <description>The SF-36 V2 consists of 36 questions covering 8 health domains: physical functioning (10 items), bodily pain (2 items), role limitations due to physical problems (4 items), role limitations due to emotional problems (3 items), general health perceptions (5 items), mental health (5 items), social function (2 items), and vitality (4 items). The physical functioning subscore and vitality subscore are reported. Each scale was transformed into 0-100 score, with higher scores indicating better health status. Baseline score was defined as the last physical functioning value or vitality value, as applicable, prior to the first dose of study drug.</description>
          <population>FAS Population included all randomized/enrolled participants who received at least 1 dose of study drug and had baseline and at least 1 postdose Hb assessment. Here, 'Overall number of participants analyzed' signifies participants evaluable for this outcome measure and 'Number Analyzed' signifies participants evaluable for this outcome measure at specified timepoint.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="368"/>
                <count group_id="O2" value="369"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Physical functioning subscore: Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="368"/>
                    <count group_id="O2" value="369"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.55" spread="11.202"/>
                    <measurement group_id="O2" value="39.63" spread="11.368"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical functioning subscore: Change at Weeks 12 to 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="326"/>
                    <count group_id="O2" value="352"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.15" spread="7.443"/>
                    <measurement group_id="O2" value="-0.20" spread="6.380"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vitality subscore: Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="368"/>
                    <count group_id="O2" value="369"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.65" spread="10.111"/>
                    <measurement group_id="O2" value="51.27" spread="9.841"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vitality subscore: Change at Weeks 12 to 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="326"/>
                    <count group_id="O2" value="352"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.92" spread="7.007"/>
                    <measurement group_id="O2" value="0.30" spread="7.041"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline (Day 1, Week 0) up to 28 days after the last dose of study drug (maximum treatment duration was 183.7 weeks for roxadustat and 180.4 weeks for epoetin alfa). Mortality presented is for the timeframe of Baseline (Day 1, Week 0) up to end of treatment (maximum treatment duration was 183.7 weeks for roxadustat and 180.4 weeks for epoetin alfa).</time_frame>
      <desc>The Safety population included all randomized participants who received at least 1 dose of study medication.</desc>
      <group_list>
        <group group_id="E1">
          <title>Roxadustat</title>
          <description>Participants received roxadustat tablets, administered orally TIW. Initial roxadustat dose was based on the participant's average prescribed ESA dose in the 4 weeks (if on epoetin or darbepoetin or 8 weeks (if on Mircera®) prior to randomization. Dose adjustments were permitted to maintain a Hb level of approximately 11 g/dL. The maximum roxadustat dose was 3.0 mg/kg per dose or 400 mg per administration (whichever was lower). The maximum treatment duration was 183.7 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Epoetin Alfa</title>
          <description>Participants on HD received epoetin alfa, administered IV TIW and participants on home HD or PD received epoetin alfa, administered SC. Initial epoetin alfa dose was based on the participant's average weekly prescribed ESA dose in 4 weeks prior to randomization if on epoetin or darbepoetin, and average monthly (4-week) prescribed ESA dose in 8 weeks prior to randomization if on Mircera®. In case of a change in route of administration from SC to IV (TIW), the initial dose of IV epoetin alfa was determined by the investigator per local SOC. Dose adjustments followed the recommendations as per the approved country-specific product label (USPI or SmPC) or local SOC. The maximum treatment duration was 180.4 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="70" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="242" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="248" subjects_at_risk="370"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Haemorrhagic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Coagulopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Disseminated intravascular coagulation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Haemolysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Nephrogenic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Cardiorespiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Pulseless electrical activity</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Acute left ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Aortic valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Bundle branch block left</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Cardiovascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Chronic left ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Hypertensive heart disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Ischaemic cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Mitral valve stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Supraventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Tachyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="370"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Arteriovenous malformation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Deafness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperparathyroidism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Hyperparathyroidism secondary</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Hyperparathyroidism tertiary</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Diabetic gastroparesis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Enterocutaneous fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Erosive duodenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Faecaloma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Gastroduodenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Gastrointestinal necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Haemorrhagic erosive gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Impaired gastric emptying</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Incarcerated umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Irritable bowel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Mallory-Weiss syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Mesenteric vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Oesophageal polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Peptic ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Reactive gastropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Small intestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Tongue dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Uraemic gastropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="370"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Complication associated with device</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Drowning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Generalised oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Hypothermia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Multiple organ dysfunction syndrome</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Pelvic mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Peripheral swelling</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Sudden cardiac death</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Hepatosplenomegaly</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Ischaemic hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Anaphylactic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Kidney transplant rejection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula site infection</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Staphylococcal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Arteriovenous graft site infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Abscess oral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Abscess soft tissue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Arthritis infective</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Atypical pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Beta haemolytic streptococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Cardiac valve vegetation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Cellulitis staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Citrobacter sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Device related sepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Endocarditis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Enterococcal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Enterococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Escherichia bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Escherichia infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Escherichia sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Extradural abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Eye infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Furuncle</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Gastroenteritis clostridial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Graft infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Haemophilus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Implant site infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Infected seroma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Infectious colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Infectious pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Intervertebral discitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Klebsiella bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Klebsiella sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Ludwig angina</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Necrotising fasciitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Osteomyelitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Osteomyelitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Osteomyelitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Pelvic abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Perirectal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Pharyngitis streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Proteus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Pseudomonal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Septic embolus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Septic phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Streptococcal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Streptococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Subacute endocarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Tracheobronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Urinary tract infection enterococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Urinary tract infection fungal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Vascular access site infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Vulval abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Vulval cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Wound infection staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Wound sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Gun shot wound</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arteriovenous fistula thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Arteriovenous graft thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula site complication</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula site haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Anastomotic ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula site haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Arteriovenous graft site haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Arteriovenous graft site haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Arteriovenous graft site stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Complications of transplanted kidney</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Craniocerebral injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Graft thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Jaw fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Ligament injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Pneumothorax traumatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Post procedural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Postoperative ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Postoperative wound complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Procedural hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Seroma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Shunt thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Spinal column injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Subdural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Vascular access malfunction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Vascular access site haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Vascular access site pseudoaneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Vascular graft complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Vascular graft occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Vascular graft thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Activated partial thromboplastin time prolonged</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Troponin increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Hypervolaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Calciphylaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Hyperglycaemic hyperosmolar nonketotic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Hypovolaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Lactic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Obesity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Type 1 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Brown tumour</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Cervical spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Costochondritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Joint effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Mobility decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Myositis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Uraemic myopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Benign pleural neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Carcinoid tumour of the stomach</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Cholangiocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Colorectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Gastrointestinal stromal tumour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Large granular lymphocytosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm of thorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Metastases to bone</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Metastatic renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Myelodysplastic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Nasopharyngeal neoplasm benign</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Oesophageal carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Parathyroid tumour benign</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Pericardial effusion malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Plasma cell myeloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Metabolic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Hypoxic-ischaemic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Allodynia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Altered state of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Brain injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Brain oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Cerebellar stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Cervical radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Dementia Alzheimer's type</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Facial paralysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Haemorrhagic cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Hepatic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Intracranial aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Ischaemic cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Ischaemic strok</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Parkinson's disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Posterior reversible encephalopathy syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Thalamic infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Thoracic outlet syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Acute psychosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Anxiety disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Azotaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>End stage renal disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Renal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Renal mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Menometrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Postmenopausal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Bronchitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Chronic respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Lung infiltration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Mediastinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Pulmonary congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="370"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic foot</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Dermatitis bullous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Hypersensitivity vasculitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Panniculitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Accelerated hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Brachiocephalic vein occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Dry gangrene</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Essential hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Extremity necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Hypertensive emergency</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Hypovolaemic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Iliac vein occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Intermittent claudication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Malignant hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Pelvic venous thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Peripheral artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Peripheral artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Peripheral embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Secondary hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Shock haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Steal syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Superior vena cava stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Superior vena cava syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Venous stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Venous thrombosis limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="286" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="292" subjects_at_risk="370"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="370"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="370"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="60" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="69" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="370"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Peripheral swelling</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Face oedema</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="370"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="370"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arteriovenous fistula site complication</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="71" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Arteriovenous graft thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Vascular graft complication</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="370"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Iron deficiency</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="370"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="370"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="370"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="370"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="69" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="64" subjects_at_risk="370"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="370"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="370"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="370"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The multisite consortium can publish any time after the data is collected and analyzed by FibroGen.&#xD;
The investigator can only publish after the multisite consortium publishes (or tries to publish and fails).&#xD;
FibroGen has 60 days to review a publication and can extend the embargo up to an additional 120 days (or 180 total).</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Trial Information Desk</name_or_title>
      <organization>FibroGen, Inc.</organization>
      <phone>415-978-1441</phone>
      <email>064study@fibrogen.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

